A review of gaucher disease pathophysiology, clinical presentation and treatments

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Stirnemann, Jér Ôme ^a   Belmatoug, Nadia ^b   Camou, Fabrice ^c   Serratrice, Christine ^a   Froissart, Roseline ^d   Caillaud, Catherine ^e   Levade, Thierry ^f   Astudillo, Leonardo ^g   Serratrice, Jacques ^a   Brassier, Anaïs ^h   Rose, Christian ⁱ   De Villemeur, Thierry Billette ^j   Berger, Marc G ^k  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e INSTITUT NECKER ENFANTS MALADES   (France)

^f CANCER RESEARCH CENTER OF TOULOUSE   (France)

^g CHU PURPAN   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k UNIVERSITÉ CLERMONT AUVERGNE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CCL18 CHEMOKINE; CHAPERONE; CHEMOKINE; CHITINASE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDASE BETA; GLUCOSYLCERAMIDE; MIGLUSTAT; PROSAPOSIN; UNCLASSIFIED DRUG;

BONE DENSITOMETRY; BONE MARROW BIOPSY; CARCINOGENESIS; CELL MIGRATION; CELL SUBPOPULATION; CYTOPENIA; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; GENE THERAPY; HEPATOMEGALY; HUMAN; HYPERGAMMAGLOBULINEMIA; IRON METABOLISM; LYSOSOME STORAGE DISEASE; MALIGNANT NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRENATAL DIAGNOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; REVIEW; SPLENOMEGALY; BIOLOGICAL MODEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROGNOSIS;

GAUCHER DISEASE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MONITORING, PHYSIOLOGIC; PROGNOSIS;

EID: 85013313964     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020441     Document Type: Review

References (202)

1. Ginzburg, L.; Kacher, Y.; Futerman, A.H. The pathogenesis of glycosphingolipid storage disorders. Semin. Cell Dev. Biol. 2004, 15, 417–431.
2. Hruska, K.S.; LaMarca, M.E.; Scott, C.R.; Sidransky, E. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 2008, 29, 567–583.
3. Vaccaro, A.M.; Motta, M.; Tatti, M.; Scarpa, S.; Masuelli, L.; Bhat, M.; Vanier, M.T.; Tylki-Szymanska, A.; Salvioli, R. Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum. Mol. Genet. 2010, 19, 2987–2997.
4. Sidransky, E. Gaucher disease: Insights from a rare Mendelian disorder. Discov. Med. 2012, 14, 273–281. [PubMed]
5. Grabowski, G.A. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 2008, 372, 1263–1271.
6. Stirnemann, J.; Vigan, M.; Hamroun, D.; Heraoui, D.; Rossi-Semerano, L.; Berger, M.G.; Rose, C.; Camou, F.; de Roux-Serratrice, C.; Grosbois, B.; et al. The French Gaucher’s disease registry: Clinical characteristics, complications and treatment of 562 patients. Orphanet J. Rare Dis. 2012, 7, 77.
7. Lee, R.E. The fine structure of the cerebroside occurring in Gaucher’s disease. Proc. Natl. Acad. Sci. USA 1968, 61, 484–489.
8. Mikosch, P.; Hughes, D. An overview on bone manifestations in Gaucher disease. Wiener Med. Wochenschr. 2010, 160, 609–624.
9. Orvisky, E.; Park, J.K.; LaMarca, M.E.; Ginns, E.I.; Martin, B.M.; Tayebi, N.; Sidransky, E. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: Correlation with phenotype and genotype. Mol. Genet. Metab. 2002, 76, 262–270.
10. Kinghorn, K.J.; Gronke, S.; Castillo-Quan, J.I.; Woodling, N.S.; Li, L.; Sirka, E.; Gegg, M.; Mills, K.; Hardy, J.; Bjedov, I.; et al. A Drosophila model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by rapamycin. J. Neurosci. 2016, 36, 11654–11670.
11. Boven, L.A.; van Meurs, M.; Boot, R.G.; Mehta, A.; Boon, L.; Aerts, J.M.; Laman, J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 2004, 122, 359–369.
12. Mucci, J.M.; Cuello, M.F.; Kisinovsky, I.; Larroude, M.; Delpino, M.V.; Rozenfeld, P.A. Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology. Blood Cells Mol. Dis. 2015, 55, 134–143.
13. Aflaki, E.; Moaven, N.; Borger, D.K.; Lopez, G.; Westbroek, W.; Chae, J.J.; Marugan, J.; Patnaik, S.; Maniwang, E.; Gonzalez, A.N.; et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 2016, 15, 77–88.
14. Allen, M.J.; Myer, B.J.; Khokher, A.M.; Rushton, N.; Cox, T.M. Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: Increased release of interleukin-6 and interleukin-10. Mon. J. Assoc. Phys. 1997, 90, 19–25.
15. Barak, V.; Acker, M.; Nisman, B.; Kalickman, I.; Abrahamov, A.; Zimran, A.; Yatziv, S. Cytokines in Gaucher’s disease. Eur. Cytokine Netw. 1999, 10, 205–210.
16. Hollak, C.E.; Evers, L.; Aerts, J.M.; van Oers, M.H. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol. Dis. 1997, 23, 201–212.
17. van Breemen, M.J.; de Fost, M.; Voerman, J.S.; Laman, J.D.; Boot, R.G.; Maas, M.; Hollak, C.E.; Aerts, J.M.; Rezaee, F. Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher disease. Biochim. Biophys. Acta 2007, 1772, 788–796.
18. Mistry, P.K.; Liu, J.; Yang, M.; Nottoli, T.; McGrath, J.; Jain, D.; Zhang, K.; Keutzer, J.; Chuang, W.L.; Mehal, W.Z.; et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. USA 2010, 107, 19473–19478.
19. Dekker, N.; van Dussen, L.; Hollak, C.E.; Overkleeft, H.; Scheij, S.; Ghauharali, K.; van Breemen, M.J.; Ferraz, M.J.; Groener, J.E.; Maas, M.; et al. Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118, e118–e127.
20. Mistry, P.K.; Liu, J.; Sun, L.; Chuang, W.L.; Yuen, T.; Yang, R.; Lu, P.; Zhang, K.; Li, J.; Keutzer, J.; et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc. Natl. Acad. Sci. USA 2014, 111, 4934–4939.
21. Hong, Y.B.; Kim, E.Y.; Jung, S.C. Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: A possible role in the neuronal loss. J. Hum. Genet. 2004, 49, 349–354.
22. Rolfs, A.; Giese, A.K.; Grittner, U.; Mascher, D.; Elstein, D.; Zimran, A.; Bottcher, T.; Lukas, J.; Hubner, R.; Golnitz, U.; et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE 2013, 8, e79732.
23. Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.; Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427, 355–360.
24. Lecourt, S.; Vanneaux, V.; Cras, A.; Freida, D.; Heraoui, D.; Herbi, L.; Caillaud, C.; Chomienne, C.; Marolleau, J.P.; Belmatoug, N.; et al. Bone marrow microenvironment in an in vitro model of Gaucher disease: Consequences of glucocerebrosidase deficiency. Stem Cells Dev. 2012, 21, 239–248.
25. Campeau, P.M.; Rafei, M.; Boivin, M.N.; Sun, Y.; Grabowski, G.A.; Galipeau, J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 2009, 114, 3181–3190.
26. Berger, J.; Lecourt, S.; Vanneaux, V.; Rapatel, C.; Boisgard, S.; Caillaud, C.; Boiret-Dupre, N.; Chomienne, C.; Marolleau, J.P.; Larghero, J.; et al. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br. J. Haematol. 2010, 150, 93–101.
27. Taddei, T.H.; Dziura, J.; Chen, S.; Yang, R.; Hyogo, H.; Sullards, C.; Cohen, D.E.; Pastores, G.; Mistry, P.K. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: Characterizing the biliary phenotype of type 1 Gaucher disease. J. Inherit. Metab. Dis. 2010, 33, 291–300.
28. Ron, I.; Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 2005, 14, 2387–2398.
29. Yang, C.; Wang, H.; Zhu, D.; Hong, C.S.; Dmitriev, P.; Zhang, C.; Li, Y.; Ikejiri, B.; Brady, R.O.; Zhuang, Z. Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation. Proc. Natl. Acad. Sci. USA 2015, 112, 1137–1142.
30. Reczek, D.; Schwake, M.; Schroder, J.; Hughes, H.; Blanz, J.; Jin, X.; Brondyk, W.; Van Patten, S.; Edmunds, T.; Saftig, P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase. Cell 2007, 131, 770–783.
31. Berkovic, S.F.; Dibbens, L.M.; Oshlack, A.; Silver, J.D.; Katerelos, M.; Vears, D.F.; Lullmann-Rauch, R.; Blanz, J.; Zhang, K.W.; Stankovich, J.; et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 2008, 82, 673–684. [PubMed]
32. Schroen, B.; Leenders, J.J.; van Erk, A.; Bertrand, A.T.; van Loon, M.; van Leeuwen, R.E.; Kubben, N.; Duisters, R.F.; Schellings, M.W.; Janssen, B.J.; et al. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J. Exp. Med. 2007, 204, 1227–1235.
33. Velayati, A.; DePaolo, J.; Gupta, N.; Choi, J.H.; Moaven, N.; Westbroek, W.; Goker-Alpan, O.; Goldin, E.; Stubblefield, B.K.; Kolodny, E.; et al. A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 2011, 32, 1232–1238.
34. Jian, J.; Zhao, S.; Tian, Q.Y.; Liu, H.; Zhao, Y.; Chen, W.C.; Grunig, G.; Torres, P.A.; Wang, B.C.; Zeng, B.; et al. Association between progranulin and Gaucher disease. EBioMedicine 2016, 11, 127–137.
35. Jian, J.; Tian, Q.Y.; Hettinghouse, A.; Zhao, S.; Liu, H.; Wei, J.; Grunig, G.; Zhang, W.; Setchell, K.D.; Sun, Y.; et al. Progranulin recruits HSP70 to β-Glucocerebrosidase and is therapeutic against Gaucher disease. EBioMedicine 2016, 13, 212–224.
36. Petkau, T.L.; Leavitt, B.R. Progranulin in neurodegenerative disease. Trends Neurosci. 2014, 37, 388–398.
37. Biegstraaten, M.; van Schaik, I.N.; Aerts, J.M.; Langeveld, M.; Mannens, M.M.; Bour, L.J.; Sidransky, E.; Tayebi, N.; Fitzgibbon, E.; Hollak, C.E. A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol. Dis. 2011, 46, 39–41.
38. Elstein, D.; Gellman, A.; Altarescu, G.; Abrahamov, A.; Hadas-Halpern, I.; Phillips, M.; Margalit, M.; Lebel, E.; Itzchaki, M.; Zimran, A. Disease severity in sibling pairs with type 1 Gaucher disease. J. Inherit. Metab. Dis. 2010, 33, 79–83.
39. Gonzalez, A.; Valeiras, M.; Sidransky, E.; Tayebi, N. Lysosomal integral membrane protein-2: A new player in lysosome-related pathology. Mol. Genet. Metab. 2014, 111, 84–91.
40. Aharon-Peretz, J.; Badarny, S.; Rosenbaum, H.; Gershoni-Baruch, R. Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype-genotype correlation. Neurology 2005, 65, 1460–1461.
41. Clark, L.N.; Ross, B.M.; Wang, Y.; Mejia-Santana, H.; Harris, J.; Louis, E.D.; Cote, L.J.; Andrews, H.; Fahn, S.; Waters, C.; et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007, 69, 1270–1277.
42. Sato, C.; Morgan, A.; Lang, A.E.; Salehi-Rad, S.; Kawarai, T.; Meng, Y.; Ray, P.N.; Farrer, L.A.; St George-Hyslop, P.; Rogaeva, E. Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov. Disord. 2005, 20, 367–370.
43. Sidransky, E.; Nalls, M.A.; Aasly, J.O.; Aharon-Peretz, J.; Annesi, G.; Barbosa, E.R.; Bar-Shira, A.; Berg, D.; Bras, J.; Brice, A.; et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 2009, 361, 1651–1661.
44. Lesage, S.; Patin, E.; Condroyer, C.; Leutenegger, A.L.; Lohmann, E.; Giladi, N.; Bar-Shira, A.; Belarbi, S.; Hecham, N.; Pollak, P.; et al. Parkinson’s disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum. Mol. Genet. 2010, 19, 1998–2004.
45. Liu, G.; Boot, B.; Locascio, J.J.; Jansen, I.E.; Winder-Rhodes, S.; Eberly, S.; Elbaz, A.; Brice, A.; Ravina, B.; van Hilten, J.J.; et al. Neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Ann. Neurol. 2016, 80, 674–685.
46. Cilia, R.; Tunesi, S.; Marotta, G.; Cereda, E.; Siri, C.; Tesei, S.; Zecchinelli, A.L.; Canesi, M.; Mariani, C.B.; Meucci, N.; et al. Survival and dementia in GBA-associated Parkinson’s disease: The mutation matters. Ann. Neurol. 2016, 80, 662–673.
47. Mazzulli, J.R.; Xu, Y.H.; Sun, Y.; Knight, A.L.; McLean, P.J.; Caldwell, G.A.; Sidransky, E.; Grabowski, G.A.; Krainc, D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146, 37–52.
48. Yap, T.L.; Gruschus, J.M.; Velayati, A.; Westbroek, W.; Goldin, E.; Moaven, N.; Sidransky, E.; Lee, J.C. α-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 2011, 286, 28080–28088.
49. Murphy, K.E.; Gysbers, A.M.; Abbott, S.K.; Tayebi, N.; Kim, W.S.; Sidransky, E.; Cooper, A.; Garner, B.; Halliday, G.M. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease. Brain J. Neurol. 2014, 137, 834–848.
50. Yap, T.L.; Velayati, A.; Sidransky, E.; Lee, J.C. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 2013, 108, 56–64.
51. Gruschus, J.M.; Jiang, Z.; Yap, T.L.; Hill, S.A.; Grishaev, A.; Piszczek, G.; Sidransky, E.; Lee, J.C. Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C. Biochem. Biophys. Res. Commun. 2015, 457, 561–566.
52. Ron, I.; Rapaport, D.; Horowitz, M. Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease. Hum. Mol. Genet. 2010, 19, 3771–3781.
53. Barkhuizen, M.; Anderson, D.G.; Grobler, A.F. Advances in GBA-associated Parkinson’s disease—Pathology, presentation and therapies. Neurochem. Int. 2016, 93, 6–25.
54. Cullen, V.; Sardi, S.P.; Ng, J.; Xu, Y.H.; Sun, Y.; Tomlinson, J.J.; Kolodziej, P.; Kahn, I.; Saftig, P.; Woulfe, J.; et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alterα-synuclein processing. Ann. Neurol. 2011, 69, 940–953.
55. Yap, T.L.; Jiang, Z.; Heinrich, F.; Gruschus, J.M.; Pfefferkorn, C.M.; Barros, M.; Curtis, J.E.; Sidransky, E.; Lee, J.C. Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy. J. Biol. Chem. 2015, 290, 744–754.
56. Siebert, M.; Sidransky, E.; Westbroek, W. Glucocerebrosidase is shaking up the synucleinopathies. Brain J. Neurol. 2014, 137, 1304–1322.
57. Horowitz, M.; Elstein, D.; Zimran, A.; Goker-Alpan, O. New directions in Gaucher disease. Hum. Mutat. 2016, 37, 1121–1136.
58. Yap, T.L.; Gruschus, J.M.; Velayati, A.; Sidransky, E.; Lee, J.C. Saposin C protects glucocerebrosidase against α-synuclein inhibition. Biochemistry 2013, 52, 7161–7163.
59. Arends, M.; van Dussen, L.; Biegstraaten, M.; Hollak, C.E. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br. J. Haematol. 2013, 161, 832–842.
60. Rosenbloom, B.E.; Weinreb, N.J.; Zimran, A.; Kacena, K.A.; Charrow, J.; Ward, E. Gaucher disease and cancer incidence: A study from the Gaucher Registry. Blood 2005, 105, 4569–4572.
61. Taddei, T.H.; Kacena, K.A.; Yang, M.; Yang, R.; Malhotra, A.; Boxer, M.; Aleck, K.A.; Rennert, G.; Pastores, G.M.; Mistry, P.K. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am. J. Hematol. 2009, 84, 208–214.
62. De Fost, M.; Vom Dahl, S.; Weverling, G.J.; Brill, N.; Brett, S.; Haussinger, D.; Hollak, C.E. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol. Dis. 2006, 36, 53–58.
63. Landgren, O.; Turesson, I.; Gridley, G.; Caporaso, N.E. Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Arch. Intern. Med. 2007, 167, 1189–1194.
64. Astudillo, L.; Therville, N.; Colacios, C.; Segui, B.; Andrieu-Abadie, N.; Levade, T. Glucosylceramidases and malignancies in mammals. Biochimie 2015, 125, 267–280.
65. Braudeau, C.; Graveleau, J.; Rimbert, M.; Neel, A.; Hamidou, M.; Grosbois, B.; Besancon, A.; Giraudet, S.; Terrien, C.; Josien, R.; et al. Altered innate function of plasmacytoid dendritic cells restored by enzyme replacement therapy in Gaucher disease. Blood Cells Mol. Dis. 2013, 50, 281–288.
66. Burstein, Y.; Zakuth, V.; Rechavi, G.; Spirer, Z. Abnormalities of cellular immunity and natural killer cells in Gaucher’s disease. J. Clin. Lab. Immunol. 1987, 23, 149–151. [PubMed]
67. Pavlova, E.V.; Wang, S.Z.; Archer, J.; Dekker, N.; Aerts, J.M.; Karlsson, S.; Cox, T.M. B cell lymphoma and myeloma in murine Gaucher’s disease. J. Pathol. 2013, 231, 88–97.
68. Pavlova, E.V.; Archer, J.; Wang, S.; Dekker, N.; Aerts, J.M.; Karlsson, S.; Cox, T.M. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 2015, 235, 113–124.
69. Nair, S.; Branagan, A.R.; Liu, J.; Boddupalli, C.S.; Mistry, P.K.; Dhodapkar, M.V. Clonal immunoglobulin against lysolipids in the origin of myeloma. N. Engl. J. Med. 2016, 374, 555–561.
70. Medrano-Engay, B.; Irun, P.; Gervas-Arruga, J.; Andrade-Campos, M.; Andreu, V.; Alfonso, P.; Pocovi, M.; Giraldo, P. Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease. Blood Cells Mol. Dis. 2014, 53, 171–175.
71. Stirnemann, J.; Boutten, A.; Vincent, C.; Mekinian, A.; Heraoui, D.; Fantin, B.; Fain, O.; Mentre, F.; Belmatoug, N. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. Blood Cells Mol. Dis. 2011, 46, 34–38.
72. Stirnemann, J.; Belmatoug, N.; Vincent, C.; Fain, O.; Fantin, B.; Mentre, F. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res. Ther. 2010, 12, R156.
73. Sidransky, E. Gaucher disease: Complexity in a “simple” disorder. Mol. Genet. Metab. 2004, 83, 6–15.
74. Charrow, J.; Andersson, H.C.; Kaplan, P.; Kolodny, E.H.; Mistry, P.; Pastores, G.; Rosenbloom, B.E.; Scott, C.R.; Wappner, R.S.; Weinreb, N.J.; et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 2000, 160, 2835–2843.
75. Kaplan, P.; Andersson, H.C.; Kacena, K.A.; Yee, J.D. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch. Pediatrics Adolesc. Med. 2006, 160, 603–608.
76. Grabowski, G.A.; Zimran, A.; Ida, H. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am. J. Hematol. 2015, 90 (Suppl. S1), S12–S18.
77. Hill, S.C.; Reinig, J.W.; Barranger, J.A.; Fink, J.; Shawker, T.H. Gaucher disease: Sonographic appearance of the spleen. Radiology 1986, 160, 631–634.
78. Neudorfer, O.; Hadas-Halpern, I.; Elstein, D.; Abrahamov, A.; Zimran, A. Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients. Am. J. Hematol. 1997, 55, 28–34.
79. Regenboog, M.; Bohte, A.E.; Somers, I.; van Delden, O.M.; Maas, M.; Hollak, C.E. Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease. Blood Cells Mol. Dis. 2016, 60, 49–57.
80. Rosenbaum, H. Hemorrhagic aspects of Gaucher disease. Rambam Maimonides Med. J. 2014, 5, e0039.
81. Gillis, S.; Hyam, E.; Abrahamov, A.; Elstein, D.; Zimran, A. Platelet function abnormalities in Gaucher disease patients. Am. J. Hematol. 1999, 61, 103–106.
82. Wenstrup, R.J.; Roca-Espiau, M.; Weinreb, N.J.; Bembi, B. Skeletal aspects of Gaucher disease: A review. Br. J. Radiol. 2002, 75 (Suppl. S1), A2–A12.
83. Clarke, L.A.; Hollak, C.E. The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 219–235.
84. Marcucci, G.; Zimran, A.; Bembi, B.; Kanis, J.; Reginster, J.Y.; Rizzoli, R.; Cooper, C.; Brandi, M.L. Gaucher disease and bone manifestations. Calcif. Tissue Int. 2014, 95, 477–494.
85. Yossipovitch, Z.H.; Herman, G.; Makin, M. Aseptic osteomyelitis in Gaucher’s disease. Isr. J. Med. Sci. 1965, 1, 531–536. [PubMed]
86. Pastores, G.M.; Wallenstein, S.; Desnick, R.J.; Luckey, M.M. Bone density in Type 1 Gaucher disease. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1996, 11, 1801–1807.
87. Deegan, P.B.; Pavlova, E.; Tindall, J.; Stein, P.E.; Bearcroft, P.; Mehta, A.; Hughes, D.; Wraith, J.E.; Cox, T.M. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine 2011, 90, 52–60.
88. Poll, L.W.; Koch, J.A.; vom Dahl, S.; Loxtermann, E.; Sarbia, M.; Niederau, C.; Haussinger, D.; Modder, U. Extraosseous manifestation of Gaucher’s disease type I: MR and histological appearance. Eur. Radiol. 2000, 10, 1660–1663.
89. Zver, S.; Bracko, M.; Andoljsek, D. Primary bone angiosarcoma in a patient with Gaucher disease. Int. J. Hematol. 2010, 92, 374–377.
90. Kenan, S.; Abdelwahab, I.F.; Hermann, G.; Klein, M.; Pastores, G. Osteoblastoma of the humerus associated with type-I Gaucher’s disease. A case report. J. Bone Joint Surg. Br. Vol. 1996, 78, 702–705.
91. Bembi, B.; Ciana, G.; Mengel,E.; Terk, M.R.; Martini, C.; Wenstrup, R.J. Bone complications in children with Gaucher disease. Br. J. Radiol. 2002, 75 (Suppl. S1), A37–A44.
92. Faden, M.A.; Krakow, D.; Ezgu, F.; Rimoin, D.L.; Lachman, R.S. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am. J. Med. Genet. Part A 2009, 149A, 1334–1345.
93. Amir, G.; Ron, N. Pulmonary pathology in Gaucher’s disease. Hum. Pathol. 1999, 30, 666–670.
94. Mistry, P.K.; Sirrs, S.; Chan, A.; Pritzker, M.R.; Duffy, T.P.; Grace, M.E.; Meeker, D.P.; Goldman, M.E. Pulmonary hypertension in type 1 Gaucher’s disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol. Genet. Metab. 2002, 77, 91–98.
95. Santamaria, F.; Parenti, G.; Guidi, G.; Filocamo, M.; Strisciuglio, P.; Grillo, G.; Farina, V.; Sarnelli, P.; Rizzolo, M.G.; Rotondo, A.; et al. Pulmonary manifestations of Gaucher disease: An increased risk for L444P homozygotes? Am. J. Respir. Critic. Care Med. 1998, 157, 985–989.
96. Santoro, D.; Rosenbloom, B.E.; Cohen, A.H. Gaucher disease with nephrotic syndrome: Response to enzyme replacement therapy. Am. J. Kidney Dis. 2002, 40, E4.
97. Goldblatt, J.; Beighton, P. Cutaneous manifestations of Gaucher disease. Br. J. Dermatol. 1984, 111, 331–334.
98. Raz, J.; Anteby, I.; Livni, N.; Benezra, D. Chronic uveitis in Gaucher’s disease. Ocular Immunol. Inflamm. 1993, 1, 119–124.
99. Bruscolini, A.; Pirraglia, M.P.; Restivo, L.; Spinucci, G.; Abbouda, A. A branch retinal artery occlusion in a patient with Gaucher disease. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250, 441–444.
100. Petrohelos, M.; Tricoulis, D.; Kotsiras, I.; Vouzoukos, A. Ocular manifestations of Gaucher’s disease. Am. J. Ophthalmol. 1975, 80, 1006–1010.
101. Roghi, A.; Poggiali, E.; Cassinerio, E.; Pedrotti, P.; Giuditta, M.; Milazzo, A.; Quattrocchi, G.; Cappellini, M.D. The role of cardiac magnetic resonance to assess the cardiac involvement in Gaucher type 1 patients: Morphological and functional evaluations. J. Cardiovasc. Med. 2016.
102. Langeveld, M.; de Fost, M.; Aerts, J.M.; Sauerwein, H.P.; Hollak, C.E. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol. Dis. 2008, 40, 428–432.
103. Elstein, D.; Rosenmann, E.; Reinus, C.; Paz, J.; Altarescu, G.; Zimran, A. Amyloidosis and gastric bleeding in a patient with Gaucher disease. J. Clin. Gastroenterol. 2003, 37, 234–237.
104. Hrebicek, M.; Zeman, J.; Musilova, J.; Hodanova, K.; Renkema, G.H.; Veprekova, L.; Ledvinova, J.; Hrebicek, D.; Sokolova, J.; Aerts, J.M.; et al. A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Virchows Arch. Int. J. Pathol. 1996, 429, 305–309.
105. Hanash, S.M.; Rucknagel, D.L.; Heidelberger, K.P.; Radin, N.S. Primary amyloidosis associated with Gaucher’s disease. Ann. Intern. Med. 1978, 89, 639–641.
106. Alcalay, R.N.; Dinur, T.; Quinn, T.; Sakanaka, K.; Levy, O.; Waters, C.; Fahn, S.; Dorovski, T.; Chung, W.K.; Pauciulo, M.; et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014, 71, 752–757.
107. Bultron, G.; Kacena, K.; Pearson, D.; Boxer, M.; Yang, R.; Sathe, S.; Pastores, G.; Mistry, P.K. The risk of Parkinson’s disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 2010, 33, 167–173.
108. Biegstraaten, M.; Mengel, E.; Marodi, L.; Petakov, M.; Niederau, C.; Giraldo, P.; Hughes, D.; Mrsic, M.; Mehta, A.; Hollak, C.E.; et al. Peripheral neuropathy in adult type 1 Gaucher disease: A 2-year prospective observational study. Brain J. Neurol. 2010, 133, 2909–2919.
109. Tajima, A.; Yokoi, T.; Ariga, M.; Ito, T.; Kaneshiro, E.; Eto, Y.; Ida, H. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol. Genet. Metab. 2009, 97, 272–277.
110. Tylki-Szymanska, A.; Vellodi, A.; El-Beshlawy, A.; Cole, J.A.; Kolodny, E. Neuronopathic Gaucher disease: Demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J. Inherit. Metab. Dis. 2010, 33, 339–346.
111. Kraoua, I.; Sedel, F.; Caillaud, C.; Froissart, R.; Stirnemann, J.; Chaurand, G.; Flodrops, H.; Tari, S.; Gourfinkel-An, I.; Mathieu, S.; et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev. 2011, 33, 131–139.
112. Abdelwahab, M.; Blankenship, D.; Schiffmann, R. Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt. Neurol. Genet. 2016, 2, e55.
113. George, R.; McMahon, J.; Lytle, B.; Clark, B.; Lichtin, A. Severe valvular and aortic arch calcification in a patient with Gaucher’s disease homozygous for the D409H mutation. Clin. Genet. 2001, 59, 360–363.
114. Cindik, N.; Ozcay, F.; Suren, D.; Akkoyun, I.; Gokdemir, M.; Varan, B.; Alehan, F.; Ozbek, N.; Tokel, K. Gaucher disease with communicating hydrocephalus and cardiac involvement. Clin. Cardiol. 2010, 33, E26–E30.
115. Tamargo, R.J.; Velayati, A.; Goldin, E.; Sidransky, E. The role of saposin C in Gaucher disease. Mol. Genet. Metab. 2012, 106, 257–263.
116. Mignot, C.; Doummar, D.; Maire, I.; De Villemeur, T.B.; French Type 2 Gaucher Disease Study Group. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006, 28, 39–48.
117. Mignot, C.; Gelot, A.; De Villemeur, T.B. Gaucher disease. Handb. Clin. Neurol. 2013, 113, 1709–1715. [PubMed]
118. Mignot, C.; Gelot, A.; Bessieres, B.; Daffos, F.; Voyer, M.; Menez, F.; Fallet Bianco, C.; Odent, S.; Le Duff, D.; Loget, P.; et al. Perinatal-lethal Gaucher disease. Am. J. Med. Genet. Part A 2003, 120A, 338–344.
119. Neufeld, E.F. Lysosomal storage diseases. Annu. Rev. Biochem. 1991, 60, 257–280.
120. Berger, J.; Stirnemann, J.; Bourgne, C.; Pereira, B.; Pigeon, P.; Heraoui, D.; Froissart, R.; Rapatel, C.; Rose, C.; Belmatoug, N.; et al. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br. J. Haematol. 2012, 157, 274–277.
121. Costello, R.; O’Callaghan, T.; Sebahoun, G. Gaucher disease and multiple myeloma. Leukemia Lymphoma 2006, 47, 1365–1368.
122. Robak, T.; Urbanska-Rys, H.; Jerzmanowski, P.; Bartkowiak, J.; Liberski, P.; Kordek, R. Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen—Diagnostic and therapeutic dilemmas. Leukemia Lymphoma 2002, 43, 2343–2350.
123. Yang, H.S.; Cho, K.S.; Park, T.S. Chronic myeloid leukemia with marked splenomegaly and pseudo-Gaucher cells. Blood Res. 2013, 48, 241.
124. Stewart, A.J.; Jones, R.D. Pseudo-Gaucher cells in myelodysplasia. J. Clin. Pathol. 1999, 52, 917–918.
125. Busarla, S.V.; Sadruddin, F.A.; Sohani, A.R. Pseudo-Gaucher cells in disseminated mycobacterial infection. Am. J. Hematol. 2013, 88, 155.
126. Horowitz, M.; Wilder, S.; Horowitz, Z.; Reiner, O.; Gelbart, T.; Beutler, E. The human glucocerebrosidase gene and pseudogene: Structure and evolution. Genomics 1989, 4, 87–96.
127. Koprivica, V.; Stone, D.L.; Park, J.K.; Callahan, M.; Frisch, A.; Cohen, I.J.; Tayebi, N.; Sidransky, E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am. J. Hum. Genet. 2000, 66, 1777–1786.
128. Yoshida, S.; Kido, J.; Matsumoto, S.; Momosaki, K.; Mitsubuchi, H.; Shimazu, T.; Sugawara, K.; Endo, F.; Nakamura, K. Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr. Int. 2016, 58, 946–949.
129. Hollak, C.E.; Belmatoug, N.; Cole, J.A.; Vom Dahl, S.; Deegan, P.B.; Goldblatt, J.; Rosenbloom, B.; van Dussen, L.; Tylki-Szymanska, A.; Weinreb, N.J.; et al. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4–5 years. Br. J. Haematol. 2012, 158, 528–538.
130. Mitrovic, M.; Elezovic, I.; Miljic, P.; Suvajdzic, N. Acquired von Willebrand syndrome in patients with Gaucher disease. Blood Cells Mol. Dis. 2014, 52, 205–207.
131. Spectre, G.; Roth, B.; Ronen, G.; Rosengarten, D.; Elstein, D.; Zimran, A.; Varon, D.; Revel-Vilk, S. Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleeding. Br. J. Haematol. 2011, 153, 372–378.
132. Grosbois, B.; Rose, C.; Noel, E.; Serratrice Cde, R.; Dobbelaere, D.; Gressin, V.; Cherin, P.; Hartmann, A.; Javier, R.M.; Clerson, P.; et al. Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy. Blood Cells Mol. Dis. 2009, 43, 138–139.
133. De Fost, M.; Out, T.A.; de Wilde, F.A.; Tjin, E.P.; Pals, S.T.; van Oers, M.H.; Boot, R.G.; Aerts, J.F.; Maas, M.; Vom Dahl, S.; et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: Data from an adult cohort of 63 patients and review of the literature. Ann. Hematol. 2008, 87, 439–449.
134. Brautbar, A.; Elstein, D.; Pines, G.; Abrahamov, A.; Zimran, A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol. Dis. 2004, 32, 214–217.
135. Hollak, C.E.; van Weely, S.; van Oers, M.H.; Aerts, J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Investig. 1994, 93, 1288–1292.
136. Van Dussen, L.; Hendriks, E.J.; Groener, J.E.; Boot, R.G.; Hollak, C.E.; Aerts, J.M. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J. Inher. Metab. Dis. 2014, 37, 991–1001.
137. Bussink, A.P.; Verhoek, M.; Vreede, J.; Ghauharali-van der Vlugt, K.; Donker-Koopman, W.E.; Sprenger, R.R.; Hollak, C.E.; Aerts, J.M.; Boot, R.G. Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J. 2009, 276, 5678–5688.
138. Bargagli, E.; Bennett, D.; Maggiorelli, C.; Di Sipio, P.; Margollicci, M.; Bianchi, N.; Rottoli, P. Human chitotriosidase: A sensitive biomarker of sarcoidosis. J. Clin. Immunol. 2013, 33, 264–270.
139. Aguilera, B.; Ghauharali van der Vlugt, K.; Helmond, M.T.; Out, J.M.; Donker-Koopman, W.E.; Groener, J.E.; Boot, R.G.; Renkema, G.H.; van der Marel, G.A.; van Boom, J.H.; et al. Transglycosidase activity of chitotriosidase: Improved enzymatic assay for the human macrophage chitinase. J. Biol. Chem. 2003, 278, 40911–40916.
140. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35.
141. Islam, S.A.; Ling, M.F.; Leung, J.; Shreffler, W.G.; Luster, A.D. Identification of human CCR8 as a CCL18 receptor. J. Exp. Med. 2013, 210, 1889–1898.
142. Bonella, F.; Costabel, U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin. Respir. Crit. Care Med. 2014, 35, 181–200.
143. Tsicopoulos, A.; Chang, Y.; Ait Yahia, S.; de Nadai, P.; Chenivesse, C. Role of CCL18 in asthma and lung immunity. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 2013, 43, 716–722.
144. Boot, R.G.; Verhoek, M.; de Fost, M.; Hollak, C.E.; Maas, M.; Bleijlevens, B.; van Breemen, M.J.; van Meurs, M.; Boven, L.A.; Laman, J.D.; et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 2004, 103, 33–39.
145. Deegan, P.B.; Moran, M.T.; McFarlane, I.; Schofield, J.P.; Boot, R.G.; Aerts, J.M.; Cox, T.M. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol. Dis. 2005, 35, 259–267.
146. Fuller, M.; Szer, J.; Stark, S.; Fletcher, J.M. Rapid, single-phase extraction of glucosylsphingosine from plasma: A universal screening and monitoring tool. Clin. Chim. Acta Int. J. Clin. Chem. 2015, 450, 6–10.
147. Mirzaian, M.; Wisse, P.; Ferraz, M.J.; Gold, H.; Donker-Koopman, W.E.; Verhoek, M.; Overkleeft, H.S.; Boot, R.G.; Kramer, G.; Dekker, N.; et al. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard. Blood Cells Mol. Dis. 2015, 54, 307–314.
148. Murugesan, V.; Chuang, W.L.; Liu, J.; Lischuk, A.; Kacena, K.; Lin, H.; Pastores, G.M.; Yang, R.; Keutzer, J.; Zhang, K.; et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am. J. Hematol. 2016, 91, 1082–1089.
149. Mekinian, A.; Stirnemann, J.; Belmatoug, N.; Heraoui, D.; Fantin, B.; Fain, O.; Charpentier, A.; Rose, C. Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment. Blood Cells Mol. Dis. 2012, 49, 53–57.
150. Stein, P.; Yu, H.; Jain, D.; Mistry, P.K. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am. J. Hematol. 2010, 85, 472–476.
151. Aerts, J.M.; Kallemeijn, W.W.; Wegdam, W.; Joao Ferraz, M.; van Breemen, M.J.; Dekker, N.; Kramer, G.; Poorthuis, B.J.; Groener, J.E.; Cox-Brinkman, J.; et al. Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies. J. Inher. Metab. Dis. 2011, 34, 605–619.
152. Hughes, D.; Cappellini, M.D.; Berger, M.; Van Droogenbroeck, J.; de Fost, M.; Janic, D.; Marinakis, T.; Rosenbaum, H.; Villarubia, J.; Zhukovskaya, E.; et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br. J. Haematol. 2007, 138, 676–686.
153. Sellos-Moura, M.; Barzegar, S.; Pan, L.; Shi, P.; Oommen, S.; Durant, J.; Ruiz, J.A. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J. Immunol. Methods 2011, 373, 45–53.
154. De Fost, M.; Langeveld, M.; Franssen, R.; Hutten, B.A.; Groener, J.E.; de Groot, E.; Mannens, M.M.; Bikker, H.; Aerts, J.M.; Kastelein, J.J.; et al. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 2009, 204, 267–272.
155. Elstein, D.; Tiomkin, M.; Hadas-Halpern, I.; Zimran, A. Organ volume by computed tomography correlates with longitudinal axis on ultrasound in patients with Gaucher disease. Ultrasound Q. 2011, 27, 225–228.
156. Vom Dahl, S.; Poll, L.; Di Rocco, M.; Ciana, G.; Denes, C.; Mariani, G.; Maas, M. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr. Med. Res. Opin. 2006, 22, 1045–1064.
157. F.; den Heeten, G.J. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging—Initial experience. Radiology 2003, 229, 554–561.
158. Fedida, B.; Touraine, S.; Stirnemann, J.; Belmatoug, N.; Laredo, J.D.; Petrover, D. Bone marrow involvement in Gaucher disease at MRI: What long-term evolution can we expect under enzyme replacement therapy? Eur. Radiol. 2015, 25, 2969–2975.
159. Hollak, C.; Maas, M.; Akkerman, E.; den Heeten, A.; Aerts, H. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol. Dis. 2001, 27, 1005–1012.
160. Maas, M.; Poll, L.W.; Terk, M.R. Imaging and quantifying skeletal involvement in Gaucher disease. Br. J. Radiol. 2002, 75 (Suppl. S1), A13–A24.
161. Mikosch, P.; Zitter, F.; Gallowitsch, H.J.; Wurtz, F.; Lind, P.; Mehta, A.B.; Hughes, D.A. Bone- and bone marrow scintigraphy in Gaucher disease type 1. Nukl. Nucl. Med. 2008, 47, N39–N43.
162. Goker-Alpan, O. Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future. Mol. Genet. Metab. 2011, 104, 438–447.
163. Andersson, H.C.; Charrow, J.; Kaplan, P.; Mistry, P.; Pastores, G.M.; Prakash-Cheng, A.; Rosenbloom, B.E.; Scott, C.R.; Wappner, R.S.; Weinreb, N.J.; et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet. Med. 2005, 7, 105–110.
164. Pastores, G.M.; Weinreb, N.J.; Aerts, H.; Andria, G.; Cox, T.M.; Giralt, M.; Grabowski, G.A.; Mistry, P.K.; Tylki-Szymanska, A. Therapeutic goals in the treatment of Gaucher disease. Sem. Hematol. 2004, 41, 4–14.
165. Beutler, E.; Demina, A.; Laubscher, K.; Garver, P.; Gelbart, T.; Balicki, D.; Vaughan, L. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol. Dis. 1995, 21, 86–108.
166. Zimran, A.; Hadas-Halpern, I.; Zevin, S.; Levy-Lahad, E.; Abrahamov, A. Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br. J. Haematol. 1993, 85, 783–786.
167. Figueroa, M.L.; Rosenbloom, B.E.; Kay, A.C.; Garver, P.; Thurston, D.W.; Koziol, J.A.; Gelbart, T.; Beutler, E. A less costly regimen of alglucerase to treat Gaucher’s disease. N. Engl. J. Med. 1992, 327, 1632–1636.
168. Wilson, C.; Spearing, R.; Teague, L.; Robertson, P.; Blacklock, H. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy. Mol. Genet. Metab. 2007, 92, 131–136.
169. Cohen, I.J.; Katz, K.; Kornreich, L.; Horev, G.; Frish, A.; Zaizov, R. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol. Dis. 1998, 24, 296–302.
170. E.; Zhang, L.; Yee, J.; Mistry, P.K.; Zimran, A.; Charrow, J.; vom Dahl, S. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet. Med. 2009, 11, 92–100.
171. Charrow, J.; Scott, C.R. Long-term treatment outcomes in Gaucher disease. Am. J. Hematol. 2015, 90 (Suppl. S1), S19–S24.
172. Stein, P.; Malhotra, A.; Haims, A.; Pastores, G.M.; Mistry, P.K. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J. Inherit. Metab. Dis. 2010, 33, 769–774.
173. Damiano, A.M.; Pastores, G.M.; Ware, J.E., Jr. The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 1998, 7, 373–386.
174. Masek, B.J.; Sims, K.B.; Bove, C.M.; Korson, M.S.; Short, P.; Norman, D.K. Quality of life assessment in adults with type 1 Gaucher disease. Qual. Life Res. Int. J. Qual. Life Asp. Treatm. Care Rehabil. 1999, 8, 263–268.
175. Weinreb, N.; Barranger, J.; Packman, S.; Prakash-Cheng, A.; Rosenbloom, B.; Sims, K.; Angell, J.; Skrinar, A.; Pastores, G.M. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin. Genet. 2007, 71, 576–588.
176. Wenstrup, R.J.; Kacena, K.A.; Kaplan, P.; Pastores, G.M.; Prakash-Cheng, A.; Zimran, A.; Hangartner, T.N. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J. Bone Miner. Res. 2007, 22, 119–126.
177. Charrow, J.; Dulisse, B.; Grabowski, G.A.; Weinreb, N.J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin. Genet. 2007, 71, 205–211.
178. Mistry, P.K.; Weinreb, N.J.; Kaplan, P.; Cole, J.A.; Gwosdow, A.R.; Hangartner, T. Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol. Dis. 2011, 46, 66–72.
179. Mistry, P.K.; Deegan, P.; Vellodi, A.; Cole, J.A.; Yeh, M.; Weinreb, N.J. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis. Br. J. Haematol. 2009, 147, 561–570.
180. Weiss, K.; Gonzalez, A.N.; Lopez, G.; Pedoeim, L.; Groden, C.; Sidransky, E. The clinical management of Type 2 Gaucher disease. Mol. Genet. Metab. 2015, 114, 110–122.
181. Elstein, D.; Hughes, D.; Goker-Alpan, O.; Stivel, M.; Baris, H.N.; Cohen, I.J.; Granovsky-Grisaru, S.; Samueloff, A.; Mehta, A.; Zimran, A. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J. Obstet. Gynaecol. Res. 2014, 40, 968–975.
182. Aerts, J.M.; Hollak, C.E.; Boot, R.G.; Groener, J.E.; Maas, M. Substrate reduction therapy of glycosphingolipid storage disorders. J. Inher. Metab. Dis. 2006, 29, 449–456.
183. Belmatoug, N.; Burlina, A.; Giraldo, P.; Hendriksz, C.J.; Kuter, D.J.; Mengel, E.; Pastores, G.M. Gastrointestinal disturbances and their management in miglustat-treated patients. J. Inherit. Metab. Dis. 2011, 34, 991–1001.
184. Lukina, E.; Watman, N.; Arreguin, E.A.; Banikazemi, M.; Dragosky, M.; Iastrebner, M.; Rosenbaum, H.; Phillips, M.; Pastores, G.M.; Rosenthal, D.I.; et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010, 116, 893–899.
185. Lukina, E.; Watman, N.; Dragosky, M.; Pastores, G.M.; Arreguin, E.A.; Rosenbaum, H.; Zimran, A.; Angell, J.; Ross, L.; Puga, A.C.; et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol. Dis. 2014, 53, 274–276.
186. Cox, T.M.; Drelichman, G.; Cravo, R.; Balwani, M.; Burrow, T.A.; Martins, A.M.; Lukina, E.; Rosenbloom, B.; Ross, L.; Angell, J.; et al. Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial. Lancet 2015, 385, 2355–2362.
187. Mistry, P.K.; Lukina, E.; Ben Turkia, H.; Amato, D.; Baris, H.; Dasouki, M.; Ghosn, M.; Mehta, A.; Packman, S.; Pastores, G.; et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: The ENGAGE randomized clinical trial. JAMA 2015, 313, 695–706.
188. Kamath, R.S.; Lukina, E.; Watman, N.; Dragosky, M.; Pastores, G.M.; Arreguin, E.A.; Rosenbaum, H.; Zimran, A.; Aguzzi, R.; Puga, A.C.; et al. Skeletal improvement in patients with Gaucher disease type 1: A phase 2 trial of oral eliglustat. Skelet. Radiol. 2014, 43, 1353–1360.
189. Belmatoug, N.; Di Rocco, M.; Fraga, C.; Giraldo, P.; Hughes, D.; Lukina, E.; Maison-Blanche, P.; Merkel, M.; Niederau, C.; Plckinger, U.; et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur. J. Intern. Med. 2017, 37, 25–32.
190. Ringden, O.; Groth, C.G.; Erikson, A.; Granqvist, S.; Mansson, J.E.; Sparrelid, E. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 1995, 59, 864–870. [PubMed]
191. Dunbar, C.E.; Kohn, D.B.; Schiffmann, R.; Barton, N.W.; Nolta, J.A.; Esplin, J.A.; Pensiero, M.; Long, Z.; Lockey, C.; Emmons, R.V.; et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 1998, 9, 2629–2640.
192. Dahl, M.; Doyle, A.; Olsson, K.; Mansson, J.E.; Marques, A.R.; Mirzaian, M.; Aerts, J.M.; Ehinger, M.; Rothe, M.; Modlich, U.; et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol. Ther. J. Am. Soc. Gene Ther. 2015, 23, 835–844.
193. Sanchez-Martinez, A.; Beavan, M.; Gegg, M.E.; Chau, K.Y.; Whitworth, A.J.; Schapira, A.H. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci. Rep. 2016, 6, 31380.
194. Parenti, G. Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics. EMBO Mol. Med. 2009, 1, 268–279.
195. Maegawa, G.H.; Tropak, M.B.; Buttner, J.D.; Rigat, B.A.; Fuller, M.; Pandit, D.; Tang, L.; Kornhaber, G.J.; Hamuro, Y.; Clarke, J.T.; et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 2009, 284, 23502–23516.
196. McNeill, A.; Magalhaes, J.; Shen, C.; Chau, K.Y.; Hughes, D.; Mehta, A.; Foltynie, T.; Cooper, J.M.; Abramov, A.Y.; Gegg, M.; et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain J. Neurol. 2014, 137, 1481–1495.
197. Kristinsson, S.Y.; Gridley, G.; Hoover, R.N.; Check, D.; Landgren, O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: A cohort study with up to 27 years follow-up. Haematologica 2014, 99, 392–398.
198. Cox, T.M.; Aerts, J.M.; Belmatoug, N.; Cappellini, M.D.; vom Dahl, S.; Goldblatt, J.; Grabowski, G.A.; Hollak, C.E.; Hwu, P.; Maas, M.; et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inherit. Metab. Dis. 2008, 31, 319–336.
199. H.N.; Weisz Hubshman, M.; Bar-Sever, Z.; Kornreich, L.; Shkalim Zemer, V.; Cohen, I.J. Re-evaluation of bone pain in patients with type 1 Gaucher disease suggests that bone crises occur in small bones as well as long bones. Blood Cells Mol. Dis. 2015, 60, 65–72.
200. Barton, N.W.; Brady, R.O.; Dambrosia, J.M.; Di Bisceglie, A.M.; Doppelt, S.H.; Hill, S.C.; Mankin, H.J.; Murray, G.J.; Parker, R.I.; Argoff, C.E.; et al. Replacement therapy for inherited enzyme deficiency— Macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med. 1991, 324, 1464–1470.
201. Vigan, M.; Stirnemann, J.; Caillaud, C.; Froissart, R.; Boutten, A.; Fantin, B.; Belmatoug, N.; Mentre, F. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. Orphanet J. Rare Dis. 2014, 9, 95.
202. Weinreb, N.J.; Goldblatt, J.; Villalobos, J.; Charrow, J.; Cole, J.A.; Kerstenetzky, M.; vom Dahl, S.; Hollak, C. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J. Inherit. Metab. Dis. 2013, 36, 543–553.